StockMacro
Company, fund or insider

Help

Menu

Pluri

$0.94 -59% in 6 monthsMarket cap $13.5M

PLUR on XNAS, Health Care, Pluri Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 76% in a year, but insiders bought $1.3M and sold nothing in 90 days.

  • Bad1 private offering and 1 S-1 share registration in last 90 days
  • BadFree cash outflow of $19.2M over 12 months, against $8.7M cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
113
Website
pluri-biotech.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $759K, net loss $10.4M.
Quarter to 30 Dec 2021: revenue –, net income -$10.9MQuarter to 31 Dec 2021: revenue –, net income -$10.9MQuarter to 31 Mar 2022: revenue $234K, net income -$9.9MQuarter to 31 Mar 2022: revenue $234K, net income -$9.9MQuarter to 30 Jun 2022: revenue $0, net income -$9.0MQuarter to 30 Jun 2022: revenue $0, net income -$9.0MQuarter to 30 Sep 2022: revenue $87K, net income -$6.1MQuarter to 30 Sep 2022: revenue $87K, net income -$6.1MQuarter to 31 Dec 2022: revenue $2K, net income -$8.1MQuarter to 31 Dec 2022: revenue $2K, net income -$8.1MQuarter to 31 Mar 2023: revenue $87K, net income -$7.6MQuarter to 31 Mar 2023: revenue $87K, net income -$7.6MQuarter to 30 Jun 2023: revenue $111K, net income -$6.5MQuarter to 30 Jun 2023: revenue $111K, net income -$6.5MQuarter to 30 Sep 2023: revenue $54K, net income -$5.0MQuarter to 30 Sep 2023: revenue $54K, net income -$5.0MQuarter to 31 Dec 2023: revenue $105K, net income -$4.9MQuarter to 31 Dec 2023: revenue $105K, net income -$4.9MQuarter to 31 Mar 2024: revenue $71K, net income -$5.3MQuarter to 31 Mar 2024: revenue $71K, net income -$5.3MQuarter to 30 Jun 2024: revenue $96K, net income -$5.7MQuarter to 30 Jun 2024: revenue $96K, net income -$5.7MQuarter to 30 Sep 2024: revenue $326K, net income -$5.9MQuarter to 30 Sep 2024: revenue $326K, net income -$5.9MQuarter to 31 Dec 2024: revenue $185K, net income -$3.0MQuarter to 31 Dec 2024: revenue $185K, net income -$3.0MQuarter to 31 Mar 2025: revenue $427K, net income -$6.1MQuarter to 31 Mar 2025: revenue $427K, net income -$6.1MQuarter to 30 Jun 2025: revenue –, net income -$7.6MQuarter to 30 Sep 2025: revenue $316K, net income -$5.8MQuarter to 30 Sep 2025: revenue $316K, net income -$5.8MQuarter to 31 Dec 2025: revenue $198K, net income -$6.5MQuarter to 31 Dec 2025: revenue $198K, net income -$6.5MQuarter to 31 Mar 2026: revenue $167K, net income -$5.5MQuarter to 31 Mar 2026: revenue $167K, net income -$5.5MQuarter to 30 Jun 2026: revenue $335K, net income -$5.9MQuarter to 30 Jun 2026: revenue $335K, net income -$5.9MQuarter to 30 Sep 2026: revenue $759K, net income -$10.4MQuarter to 30 Sep 2026: revenue $759K, net income -$10.4M
30 Dec 2021RevenueNet incomeNet losstallest bar $10.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$759K-$10.4M
30 Jun 2026$335K-$5.9M
31 Mar 2026$167K-$5.5M
31 Dec 2025$198K-$6.5M
30 Sep 2025$316K-$5.8M
30 Jun 2025–-$7.6M
31 Mar 2025$427K-$6.1M
31 Dec 2024$185K-$3.0M
30 Sep 2024$326K-$5.9M
30 Jun 2024$96K-$5.7M
31 Mar 2024$71K-$5.3M
31 Dec 2023$105K-$4.9M
30 Sep 2023$54K-$5.0M
30 Jun 2023$111K-$6.5M
31 Mar 2023$87K-$7.6M
31 Dec 2022$2K-$8.1M
30 Sep 2022$87K-$6.1M
30 Jun 2022$0-$9.0M
31 Mar 2022$234K-$9.9M
31 Dec 2021–-$10.9M
30 Dec 2021–-$10.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.5M $1.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +10% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$28.4M -$22.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.65 -$3.12
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 52.0% 42.9% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$19.2M -$21.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $8.7M $16.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 9.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
PluriPLUR (this company) $13.5Mloss9.3+10%–
Acumen PharmaceuticalsABOS $13.5Mloss–––
Estrella ImmunopharmaESLA $14.1Mloss–––
Passage BioPASG $12.6Mloss–––
BioStem TechnologiesBSEM $12.2M––––
BioCardiaBCDA $11.9Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$1.3M

bought $1.3M, sold $0

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

8.8%

1.3M shares held by 13F filers (30 Sep 2026) of 14.4M outstanding (11 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.5%

77K shares sold short (30 Oct 2026) of 14.4M outstanding (11 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

77K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+265%

21K shares sold short in the report before, 77K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

41%

41% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 33%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

3

3 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

3 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.94 on 20 Nov 2026, -76% over 12 months (12-month range $0.85 to $3.90)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $1.3M in the last 12 months (the 12 months before: $6.6M).
Revenue per quarter. Revenue $759K in the latest quarter, +140% on a year earlier.
Capital spending per quarter. Capital spending $3K in the latest quarter, -97% on a year earlier.
Institutional holders (13F filers). 18 13F filers reported holding it in the latest 13F quarter, +5.9% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
6 Oct 20268-K and other filingsRegistered new securities for sale (S-1)
4 Sep 20268-K and other filingsPrivate placement of securities (Form D)
13 Jul 20268-K and other filingsDelisting notice or listing transfer
22 Jun 20268-K and other filingsDirector or officer change
22 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Jan 20268-K and other filingsDelisting notice or listing transfer
9 Dec 20258-K and other filingsDirector or officer change
16 Oct 20258-K and other filingsDirector or officer change
11 Sep 20258-K and other filingsDirector or officer change
3 Jul 20258-K and other filingsDirector or officer change
3 Jul 20258-K and other filingsDelisting notice or listing transfer
3 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Mar 20258-K and other filingsPrivate placement of securities (Form D)
29 Jan 20258-K and other filingsDirector or officer change
29 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jan 20258-K and other filingsDelisting notice or listing transfer
27 Nov 20248-K and other filingsDelisting notice or listing transfer
23 Jul 20248-K and other filingsDelisting notice or listing transfer
2 Jul 20248-K and other filingsDirector or officer change
2 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 May 20248-K and other filingsDelisting notice or listing transfer
19 Oct 20238-K and other filingsDelisting notice or listing transfer
13 Jul 20238-K and other filingsDirector or officer change
13 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Apr 20238-K and other filingsDelisting notice or listing transfer
30 Dec 20228-K and other filingsPrivate placement of securities (Form D)
19 Dec 20228-K and other filingsDirector or officer change
19 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Oct 20228-K and other filingsDelisting notice or listing transfer
23 Jun 20228-K and other filingsDirector or officer change
23 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: $145K published
Month from 1 Dec 2022: -$2K published
Month from 1 Jul 2025: $4.5M published
Month from 1 Nov 2025: $2.1M published
Month from 1 Oct 2026: $1.3M published
Revenue per quarter
Quarter ended 31 Mar 2022: $234K; public on 10 May 2022
Quarter ended 30 Jun 2022: $0; public on 22 Sep 2022
Quarter ended 30 Sep 2022: $87K; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $2K; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $87K, -63% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $111K; public on 13 Sep 2023
Quarter ended 30 Sep 2023: $54K, -38% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $105K, +5150% on a year earlier; public on 13 Feb 2024
Quarter ended 31 Mar 2024: $71K, -18% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $96K, -14% on a year earlier; public on 19 Sep 2024
Quarter ended 30 Sep 2024: $326K, +504% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $185K, +76% on a year earlier; public on 12 Feb 2025
Quarter ended 31 Mar 2025: $427K, +501% on a year earlier; public on 14 May 2025
Quarter ended 30 Sep 2025: $316K, -3.1% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $198K, +7.0% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $167K, -61% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $335K; public on 11 Sep 2026
Quarter ended 30 Sep 2026: $759K, +140% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $29K, -78% on a year earlier; public on 8 Feb 2022
Quarter ended 31 Mar 2022: $37K, -70% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $199K, +374% on a year earlier; public on 22 Sep 2022
Quarter ended 30 Sep 2022: $73K, +387% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $68K, +134% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $24K, -35% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $97K, -51% on a year earlier; public on 13 Sep 2023
Quarter ended 30 Sep 2023: $103K, +41% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $121K, +78% on a year earlier; public on 13 Feb 2024
Quarter ended 31 Mar 2024: $89K, +271% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $10K, -90% on a year earlier; public on 19 Sep 2024
Quarter ended 30 Sep 2024: $208K, +102% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $112K, -7.4% on a year earlier; public on 12 Feb 2025
Quarter ended 31 Mar 2025: $577K, +548% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $721K, +7110% on a year earlier; public on 18 Sep 2025
Quarter ended 30 Sep 2025: $116K, -44% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Mar 2026: $44K, -92% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $26K, -96% on a year earlier; public on 11 Sep 2026
Quarter ended 30 Sep 2026: $3K, -97% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
30 Sep 2022 report: 31; public on 14 Nov 2022
31 Dec 2022 report: 28; public on 14 Feb 2023
31 Mar 2023 report: 29; public on 15 May 2023
30 Jun 2023 report: 29; public on 14 Aug 2023
30 Sep 2023 report: 26; public on 14 Nov 2023
31 Dec 2023 report: 24; public on 14 Feb 2024
31 Mar 2024 report: 22; public on 15 May 2024
30 Jun 2024 report: 15; public on 14 Aug 2024
30 Sep 2024 report: 14; public on 14 Nov 2024
31 Dec 2024 report: 19; public on 14 Feb 2025
31 Mar 2025 report: 18; public on 15 May 2025
30 Jun 2025 report: 19; public on 14 Aug 2025
30 Sep 2025 report: 17; public on 14 Nov 2025
31 Dec 2025 report: 14; public on 17 Feb 2026
31 Mar 2026 report: 14; public on 15 May 2026
30 Jun 2026 report: 17; public on 14 Aug 2026
30 Sep 2026 report: 18; public on 16 Nov 2026
Federal obligations
Month from 1 Jul 2023: $1.4M published
Month from 1 Aug 2023: $0 published
Month from 1 Jun 2024: $1.4M published
Month from 1 Apr 2025: $0 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $13.7M (30 Sep 2026), 4.1× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $1.3M in the last 12 months (the 12 months before: $6.6M).
  • Revenue per quarter: Revenue $759K in the latest quarter, +140% on a year earlier.
  • Capital spending per quarter: Capital spending $3K in the latest quarter, -97% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 38 insider trades

Last 90 days: no sales; 1 purchase, $1.3M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
27 Oct 2026Alexandre Weinstein ManieuDirector, 10% ownerBuy833,334$1.50$1.3MForm 4
20 Nov 2025Alexandre Weinstein Manieu and 1 otherDirector, 10% ownerBuy452,702$4.61$2.1MForm 4
1 Jul 2025Chutzpah Holdings Ltd and 1 otherDirectorBuy976,139$4.61$4.5MForm 4
22 Dec 2022Zami AbermanDirectorSell2,000$0.97$2KForm 4
14 Feb 2022Zami AbermanDirectorBuy80,616$1.80$145KForm 4
1 Jun 2021Clover Wolf Capital - Limited Partnership10% ownerSell355,570$3.70$1.3MForm 4
27 May 2021Clover Wolf Capital - Limited Partnership10% ownerSell410,376$3.86$1.6MForm 4
4 May 2021Clover Wolf Capital - Limited Partnership10% ownerSell189,725$4.61$875KForm 4

18 institutions reported shares at the end of Q3 2026, 9% of the shares outstanding; 3 opened a position, 2 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Armistice Capital, LLC1.2M8.35%$1.2MNew+1.2M
Citadel Advisors LLC46K0.32%$45KNew+46K
Renaissance Technologies LLC16K0.11%$16K-2,268-12%
Morgan Stanley2,9820.02%$3KNo change
EverSource Wealth Advisors, LLC2,0000.01%$2KNo change
UBS Group AG5040.00%$504-1,414-74%
Barclays PLC3660.00%$366New+366
SIMA Wealth Partners, LLC3500.00%$350No change
Wells Fargo & Company1850.00%$185No change
JPMorgan Chase & Co1250.00%$120No change

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 30 Jun 2023. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
30 Jun 2023Department of Health and Human ServicesNational Institutes of Health$1.4Mup to $4.2MDEVELOPMENT OF PLX-R18 CELL THERAPY AS A COUNTERMEASURE FOR HEMATOPOIETIC ACUTE RADIATION SYNDROMEUSAspending

Company events

All 63 company events

In 12 months: 6 major agreements, 2 director or officer changes, 2 delisting notices, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Oct 2026Signed a major agreementSame filing: sold shares privately8-K
20 Oct 2026Signed a major agreementSame filing: sold shares privately8-K
6 Oct 2026Registered new securities for sale (S-1)S-1
4 Sep 2026Private placement of securities (Form D)$3.7M sold of $3.7M offeredD
28 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
13 Jul 2026Delisting notice or listing transfer8-K
22 Jun 2026Director or officer change; Signed a major agreementSame filing: shareholder vote results8-K
27 Mar 2026Signed a major agreementSame filing: sold shares privately8-K

The 5 newest of 31 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Insiders record

    Manieu Alexandre Weinstein (director) bought 833,334 shares of PLUR ($1.3M)

  2. 6 Oct 2026Filings record

    Registered new securities for sale (S-1)

  3. 4 Sep 2026Filings record

    Private placement of securities (Form D)

  4. 13 Jul 2026Filings record

    Delisting notice or listing transfer

  5. 22 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 22 Jun 2026Filings record

    Director or officer change

  7. 22 Jan 2026Filings record

    Delisting notice or listing transfer

  8. 9 Dec 2025Filings record

    Director or officer change

  9. 21 Nov 2025Insiders record

    Manieu Alexandre Weinstein (director) and 1 other(s) bought 452,702 shares of PLUR ($2.1M) (dated 20 Nov 2025)

  10. 16 Oct 2025Filings record

    Director or officer change

  11. 11 Sep 2025Filings record

    Director or officer change

  12. 3 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 3 Jul 2025Filings record

    Director or officer change

  14. 3 Jul 2025Filings record

    Delisting notice or listing transfer

  15. 2 Jul 2025Insiders record

    Chutzpah Holdings Ltd (director) and 1 other(s) bought 976,139 shares of PLUR ($4.5M) (dated 1 Jul 2025)

  16. 19 Mar 2025Filings record

    Private placement of securities (Form D)

  17. 29 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 29 Jan 2025Filings record

    Director or officer change

  19. 21 Jan 2025Filings record

    Delisting notice or listing transfer

  20. 27 Nov 2024Filings record

    Delisting notice or listing transfer

  21. 23 Jul 2024Filings record

    Delisting notice or listing transfer

  22. 2 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 2 Jul 2024Filings record

    Director or officer change

  24. 31 May 2024Filings record

    Delisting notice or listing transfer

  25. 19 Oct 2023Filings record

    Delisting notice or listing transfer

  26. 13 Jul 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 13 Jul 2023Filings record

    Director or officer change

  28. 6 Jul 2023Government contracts record

    PLURI BIOTECH LTD: new Department of Health and Human Services contract 75N93023C00012 ($1.4M) (dated 30 Jun 2023)

  29. 25 Apr 2023Filings record

    Delisting notice or listing transfer

  30. 30 Dec 2022Filings record

    Private placement of securities (Form D)

  31. 19 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 19 Dec 2022Filings record

    Director or officer change

  33. 13 Oct 2022Filings record

    Delisting notice or listing transfer

  34. 23 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 23 Jun 2022Filings record

    Director or officer change

  36. 15 Feb 2022Insiders record

    Aberman Zami (director) bought 80,616 shares of PSTI ($145,109) (dated 14 Feb 2022)

  37. 19 Jul 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 19 Jul 2021Filings record

    Director or officer change

  39. 25 Mar 2021Filings record

    Changed its auditor

  40. 6 Jan 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 83 entries; narrow the window or the kind of data to see older ones.

Not listed: 140 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001158780
Ticker
PLUR
Domain
pluri-biotech.com
Employer name
Ai Software LLC (1 unverified)
Fein
81-4805297 (1 unverified)
Name
(100% held by Ever After Foods Ltd.), AI SOFTWARE INC, Cellav Health and Aesthetics Ltd., incorporated, Coffeesai Ltd., incorporated under the laws of and 16 more
Uei
FBK1WNEJMQH5
Wikidata
Q7205567
Wikipedia
Pluri Inc.
  • DOL H-1B labor condition applications and PERM certifications4 data points1 Jun 2026 to 3 Aug 2026
  • SEC Form 13F institutional holdings153 data points30 Sep 2022 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)171 records13 Jan 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1038 data points30 Jun 2009 to 11 Nov 2026
  • SEC Form 4 insider transactions38 records, 116 data points16 Feb 2016 to 27 Oct 2026
  • FINRA short interest (twice monthly)309 data points29 Jul 2022 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2172 data points26 Jul 2022 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 12 data points30 Jun 2023 to 15 Apr 2025
  • Wikipedia pageviews1511 data points3 Oct 2022 to 21 Nov 2026